David Moore joined ARCH as a Senior Partner in 2026, and brings over 25 years of biopharma operational, deal-making and executive management experience. Most recently, he served as President of Novo Nordisk US and Executive Vice President of Global Business Development. During his time at Novo, Mr. Moore led the organization through several key product introductions, including the record-breaking launches of Ozempic and most recently Wegovy Pill. He has become a trusted partner in the biotech community, overseeing dozens of external innovation transactions each year, and large acquisitions like that of Catalent corporation.
Prior to rejoining Novo, Mr. Moore was an Investment Partner with Gurnet Point Capital, a venture and growth-equity firm focused on life sciences and health care services.
Earlier in his career, Mr. Moore was a CEO in the Roivant family of companies and served on the portfolio governance committee. He began his career at Johnson & Johnson, spending fourteen years gaining increased responsibility in a broad range of therapy areas in the disciplines of commercial operations, market access and business development.
Mr. Moore holds a degree in biology from Towson University, an MBA from Lehigh University and completed the graduate program in population health and health policy at Thomas Jefferson University.